Shanghai, China, August 29, 2025 – Fosun Pharma (600196.SH; 02196.HK) and Accro Bioscience (Accro) today announced that Accro will grant exclusive rights to develop, manufacture, and commercialize its independently developed, highly selective TYK2/JAK1 inhibitor to Fosun Pharma in Greater China (including Chinese Mainland, Hong Kong SAR, and Macau SAR). Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR).

Under the agreement, Accro will receive an upfront payment and near-term milestone payment totaling RMB 80 million (including an upfront payment of RMB 60 million, and a milestone payment of RMB 20 million upon completion of manufacture technology transfer), as well as up to RMB 76 million in development milestone payments. Accro will also receive commercial milestone payments and tiered royalties of up to double-digit percentages based on product sales in the licensed regions.

AC-201 is a novel, highly selective and potent oral small-molecule inhibitor of TYK2/JAK1 that binds to the pseudo kinase domain (JH2) of TYK2/JAK1, with minimal effect on the JAK2/JAK2 signaling pathway. It is being developed to treat multiple immune mediated inflammatory diseases. AC-201 has completed a Phase II clinical trial in patients with moderate-to-severe plaque psoriasis. Results indicated that after 12 weeks of treatment, all dose groups in the Phase II study met the primary endpoint and key secondary endpoints. AC-201 was generally safe and well-tolerated across all dose groups, with no adverse events (AEs) leading to discontinuation or serious adverse events (SAEs).

Dr. Xiaohu Zhang, co-founder and CEO of Accro Bioscience, said: "We are delighted to work with Fosun Pharma. Fosun's extensive clinical development experience and commercialization capabilities will accelerate the development of AC-201 and enhance drug accessibility, bringing exceptional treatment options to patients with autoimmune diseases in the region as soon as possible."

“We are delighted to enter into this collaboration with Accro. AC-201, as a highly selective TYK2/JAK1 inhibitor, demonstrates significant clinical potential in the treatment of autoimmune diseases.”Dr.Xingli Wang,Co-President of Fosun Pharma, CEO of the Global R&D Center said. “Fosun Pharma remains committed to introducing and developing innovative therapies with breakthrough significance to address unmet medical needs. This partnership will further enrich our pipeline in the immunology and inflammation field. Leveraging Fosun Pharma's established clinical development system and commercial network, we aim to accelerate the development and commercialization of AC-201 in Greater China, benefiting more patients in a timely manner. We look forward to working closely with the Accro team to drive the success of this product and provide high-quality treatment options for patients in China and around the world.”

About Accro Bioscience

Accro Bioscience is a clinical-stage biotech company with a core focus on the molecular mechanisms of regulated cell death and related pathogenesis in human diseases. The company currently has three clinical-stage assets. AC-201, a selective TYK2/JAK1 inhibitor with therapeutic potential across a broad range of immune mediated inflammatory diseases, has completed a Phase 2 clinical trial in psoriasis with positive efficacy and safety readout. The RIPK2 inhibitor, AC-101, has completed the Phase 1 study in Australia and China with excellent safety and PK/PD data, and a Ph1b trial in UC patients is currently ongoing. The RIPK1 inhibitor, AC-003, obtained Orphan Drug Designation from the FDA, has completed the Phase 1 study in China and the United States, and is currently in a Phase 1b trial for the treatment of aGvHD patients. Accro Bioscience owns global rights of the assets with 25 patents issued in China, Japan, US, Korea and EU.

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy - Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powereddrug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide.

Looking ahead, Fosun Pharma remains anchored in its core values of “Care for life, Continuous innovation, Pursuit of excellence, and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.